Survey of oncologists finds knowledge gap on medical marijuana
As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers.
Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial oncology at the Dana-Farber Cancer Institute, led a survey of cancer physicians around the country, exploring their attitudes and actions on medical marijuana.
The survey was sent to 400 oncologists, with a 63 percent response rate. We asked Braun to outline her findings, which were published last month in the Journal of Clinical Oncology.
Stories you may be interested in
Thanks to the Farm Bill, Hemp Is Legal. Here’s What It Means for CBD.
On Tuesday, the Senate voted to approve a new an $867 billion farm bill, and on Wednesday, it passed in Congress. While the bill has plenty of positive merits, the one people are perhaps most excited about is the fact that it will legalize the production, sale, and distribution of industrial hemp at a federal…
Read More 
Alternative Mississippi medical marijuana program barely wins approval from Senate
JACKSON • Legislation that would create a new medical marijuana program in Mississippi if the voter-approved Initiative 65 is overturned in court cleared the state Senate on the second try last week early on Friday morning. Senate Bill 2765, the Mississippi Medical Cannabis Act, failed by a single vote Thursday evening. But six hours later, after…
Read More 
Senate bill could legalize medical marijuana in North Carolina
GREENVILLE, N.C. (WNCT) — Medical marijuana is legal in 36 states. Now, the state General Assembly could make North Carolina the latest state to open up the market to cannabis. Medical cannabis advocates are trying to throw veterans a lifeline with Senate Bill 711. “The veteran suicide rate is twice the national average in North Carolina,…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More 
REGISTRATION NOW OPEN: Arfinn Med Medical Cannabis Efficacy Portal for Licensed Medical Professionals
Arfinn Med, the first clinician-based medical professional and patient efficacy portal for medical cannabis treatments, is now open for registrations from licensed medical professionals. The free collaborative portal allows medical professionals to register, share, research and communicate HIPAA-compliant benchmark data for medical cannabis treatments. As a free tool for physicians, Arfinn Med offers a new…
Read More 
What You Need to Know About CBD Oil
Cannabidiol (CBD) is a non-intoxicating extract from the hemp plant that is a natural remedy for many ailments like epilepsy, insomnia, nausea, anxiety and more. A popular method of taking CBD is in the form of an oil, which is made from pulling cannabidiol from the cannabis plant and diluting it with another oil. Once…
Read More